Liquidia Stock (NASDAQ:LQDA)

Forecast Revenue Ownership Financials Chart Transcripts

Previous Close

$19.60

52W Range

$8.26 - $19.94

50D Avg

$15.18

200D Avg

$13.62

Market Cap

$1.69B

Avg Vol (3M)

$2.42M

Beta

-0.01

Div Yield

-

LQDA Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

170

IPO Date

Jul 26, 2018

Website

LQDA Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/Service	Dec 20
Research and Development Services	-
Promotion Agreement	$739.63K

Fiscal year ends in Dec 24 | Currency in USD

LQDA Financial Summary

	Dec 24	Dec 23	Dec 22
Revenue	$14.00M	$17.49M	$15.94M
Operating Income	$-121.29M	$-73.38M	$-38.77M
Net Income	-	$-78.50M	$-38.37M
EBITDA	$-121.29M	$-70.05M	$-34.72M
Basic EPS	$-1.66	$-1.21	$-0.63
Diluted EPS	$-1.66	$-1.21	$-0.63

Fiscal year ends in Dec 24 | Currency in USD

Latest Earnings Call Transcripts

Q1 25May 10, 25 | 8:30 AM

Q4 24Mar 19, 25 | 8:30 AM

Q3 24Nov 13, 24 | 8:30 AM

Peer Comparison

Ticker	Company
KZR	Kezar Life Sciences, Inc.
CRNX	Crinetics Pharmaceuticals, Inc.
KNSA	Kiniksa Pharmaceuticals, Ltd.
DAWN	Day One Biopharmaceuticals, Inc.
VRCA	Verrica Pharmaceuticals Inc.
LRMR	Larimar Therapeutics, Inc.
SRRK	Scholar Rock Holding Corporation
MNKD	MannKind Corporation
UTHR	United Therapeutics Corporation